Coronary Artery Disease - Pipeline Review, H1 2017

Introduction

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 17, 7, 18 and 1 respectively. Similarly, the Universities portfolio in IND/CTA Filed and Discovery stages comprises 1 and 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017

• Table of Contents

  Table of Contents 2

  List of Tables 5

  List of Figures 6

  Introduction 7

  Global Markets Direct Report Coverage 7

  Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 8

  Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development 9

  Pipeline Overview 9

  Pipeline by Companies 10

  Pipeline by Universities/Institutes 14

  Products under Development by Companies 15

  Products under Development by Universities/Institutes 18

  Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 19

  Assessment by Target 19

  Assessment by Mechanism of Action 22

  Assessment by Route of Administration 25

  Assessment by Molecule Type 27

  Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 29

  advanceCor GmbH 29

  Akcea Therapeutics Inc 29

  Amarantus Bioscience Holdings Inc 30

  AnGes MG Inc 30

  Arena Pharmaceuticals Inc 31

  Ascendia Pharmaceuticals LLC 31

  AstraZeneca Plc 32

  Athera Biotechnologies AB 32

  Bayer AG 33

  Biscayne Pharmaceuticals Inc 33

  Capricor Therapeutics Inc 34

  Cardiome Pharma Corp 34

  CardioVascular BioTherapeutics Inc 35

  Cerenis Therapeutics Holding SA 35

  CSL Ltd 36

  Esperion Therapeutics Inc 36

  Gilead Sciences Inc 37

  HitGen LTD 37

  Human Stem Cells Institute 38

  Japan Tobacco Inc 38

  Juventas Therapeutics Inc 39

  Lee's Pharmaceutical Holdings Ltd 39

  LipimetiX Development Inc 40

  Lonestar Heart Inc 40

  MedImmune LLC 41

  Merck & Co Inc 41

  Nuo Therapeutics Inc 42

  Pfizer Inc 42

  Pharmahungary Group 43

  Proteon Therapeutics Inc 43

  Resverlogix Corp 44

  Tasly Pharmaceutical Group Co Ltd 44

  The Medicines Company 45

  Verseon Corp 45

  VESSL Therapeutics Ltd 46

  ViroMed Co Ltd 46

  Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles 47

  4-WF - Drug Profile 47

  AEM-28 - Drug Profile 48

  AEM-2802 - Drug Profile 50

  ALD-201 - Drug Profile 51

  alprostadil - Drug Profile 53

  AMRS-001 - Drug Profile 54

  anacetrapib - Drug Profile 63

  apabetalone - Drug Profile 65

  AZD-5069 - Drug Profile 77

  AZD-5718 - Drug Profile 79

  beperminogene perplasmid - Drug Profile 80

  Biologics for Acute Coronary Syndrome - Drug Profile 86

  BIS-5409 - Drug Profile 87

  bivalirudin - Drug Profile 88

  cangrelor tetrasodium - Drug Profile 89

  CAP-1002 - Drug Profile 93

  CAP-2003 - Drug Profile 99

  CER-001 - Drug Profile 101

  clopidogrel bisulphate - Drug Profile 105

  COR-2 - Drug Profile 106

  Cryocell - Drug Profile 107

  CSL-112 - Drug Profile 108

  CVBT-141H - Drug Profile 110

  dalcetrapib - Drug Profile 111

  Gemacell - Drug Profile 115

  Gene Therapy to Activate Vascular Endothelial Growth Factor for Coronary Artery Disease - Drug Profile 116

  IONIS-APOARX - Drug Profile 117

  JVS-100 - Drug Profile 120

  MEDI-6012 - Drug Profile 125

  MultiGeneAngio - Drug Profile 128

  MZ-004 - Drug Profile 129

  Neovasculgen - Drug Profile 131

  PC-mAb - Drug Profile 132

  PF-06282999 - Drug Profile 135

  PMC-6 - Drug Profile 136

  PR-15 - Drug Profile 137

  Proteins for Ischemic Heart Disease - Drug Profile 139

  ranolazine ER - Drug Profile 140

  Recombinant Protein for Cardiovascular Diseases - Drug Profile 143

  Rejuveinix - Drug Profile 144

  rivaroxaban - Drug Profile 145

  Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile 161

  Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 162

  Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 163

  temanogrel hydrochloride - Drug Profile 165

  tirofiban hydrochloride - Drug Profile 167

  TSL-0202 - Drug Profile 168

  vericiguat - Drug Profile 169

  VM-202 - Drug Profile 171

  vonapanitase - Drug Profile 175

  ZK-001 - Drug Profile 180

  Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 182

  Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 188

  Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 190

  Featured News & Press Releases 190

  Appendix 202

  Methodology 202

  Coverage 202

  Secondary Research 202

  Primary Research 202

  Expert Panel Validation 202

  Contact Us 202

  Disclaimer 203

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

47435 | GMDHC9017IDB

Number of Pages

207

Report Format

PDF

Related Reports